DeNovaMed’s groundbreaking research into novel antibiotics is now a published article in the prestigious journal Nature Communications!
In this article, DeNovaMed scientists and collaborators summarize progress on the design and optimization of hundreds of novel compounds against ACP synthase (AcpS), culminating in preclinical candidate DNM0547. The article surveys the enabling data for DNM0547 and concludes “DNM0547 is an effective topical antibiotic with
bacterial killing properties in an important area of medical concern or which there a currently no effective solutions, ischemic infections such as those present in the extremities of DFU patients that lead to hundreds of thousands of amputations per year, or systemic spread and death if amputations are not performed in a timely manner. In addition, beyond DNM0547, there are over 30 other molecules in this antibiotic family to further explore, this new antibiotic family may form the basis for several AMR programs.”
Publication of this paper is a major milestone in our research tackling antimicrobial resistance and a major validation by our peers.
Citation: Barden CJ, Wu F, Fernandez-Murray JP, Lu E, Sun S, Taylor MM, Rushton AL, Williams J, Tavasoli M, Meek A, Reddy AS, Doyle LM, Sagamanova I, Sivamuthuraman K, Boudreau RTM, Byers DM, Weaver DF, McMaster CR. Computer-aided drug design to generate a unique antibiotic family. Nat Commun. 2024 Sep 27;15(1):8317. doi: 10.1038/s41467-024-52797-2. PMID: 39333560; PMCID: PMC11436758.